NCT07649070
Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas
Not Yet Recruiting
PHASE2Ages 3–21InterventionalTreatmentM.D. Anderson Cancer CenterInvestigator-initiated
~38 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:G207
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Gregory Friedman, MD · PRINCIPAL_INVESTIGATOR · UT MD Anderson
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Patient requires an escalation in ongoing systemic corticosteroid therapy within 7 days prior to G207 inoculation
For this study, 'systemic corticosteroids' include oral, intravenous, or intramuscular formulations. A single, non-consecutive dose does not constitute exclusion. Physiologic corticosteroid replacement therapy (e.g., hydrocortisone for adrenal insufficiency), intermittent use of bronchodilators and topical steroids, is not considered immunosuppressive and does not constitute exclusion.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0